Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2012

Open Access 01-10-2012 | Original Article

Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation

Authors: Valentina Di Gialleonardo, Alberto Signore, Antoon T. M. Willemsen, Jurgen W. A. Sijbesma, Rudi A. J. O. Dierckx, Erik F. J. de Vries

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2012

Login to get access

Abstract

Purpose

N-(4-[18F]Fluorobenzoyl)interleukin-2 ([18F]FB-IL2) specifically binds to interleukin-2 receptors (IL-2R) and thus may be used to detect inflammation processes using positron emission tomography (PET). We now validated whether [18F]FB-IL2 can be used to quantify activated human peripheral blood mononuclear cells (hPBMC) in rats by pharmacokinetic modelling.

Methods

Eleven Wistar rats were subcutaneously inoculated in the shoulder with different amounts of phytohaemagglutinin (PHA) activated hPBMC 15 min before i.v. injection of [18F]FB-IL2. A 60-min dynamic PET scan was acquired and arterial blood sampling and metabolite analysis were performed. At the end of the scan, animals were terminated and the inflammatory lesion dissected. PET data were analysed using Logan and Patlak analysis as well as one-tissue and two-tissue compartment models. Model preferences according to the Akaike information criterion (AIC) and correlation between PET measurements and the number of CD25-positive cells were evaluated.

Results

A high correlation between ex vivo tracer uptake (standardized uptake value) in the xenograft and the number of inoculated CD25-positive cells was observed (R 2 = 0.90). Plasma time-activity curves showed a rapid washout of the radiopharmaceutical from blood, while the time-activity curves of the inflammatory lesions showed slower washout. Time-activity curves could be fitted well by the Logan analysis method, indicating that the binding between [18F]FB-IL2 and CD25 is reversible. AIC indicated that data could be modelled best by a two-tissue reversible compartment model. A high correlation was observed between the binding potential and the number of CD25-positive cells (R 2 = 0.876, p < 0.0001). Based on binding potential measured by PET, the limit of detection was about 160,000 CD25-positive cells per 200 μl lesion (95 % confidence).

Conclusion

[18F]FB-IL2 kinetics in this animal model of inflammation could be best described by a reversible two-tissue compartment model. The [18F]FB-IL2 binding potential is a suitable measure for accurate quantification of lymphocytic infiltration in pathological conditions with PET.
Appendix
Available only for authorised users
Literature
1.
Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 2004;33(2):109–42.PubMedCrossRef
2.
Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004;28(3):109–23.PubMedCrossRef
3.
Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010;33(2):153–65.PubMedCrossRef
4.
Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med 2010;31(5):561–74.PubMedCrossRef
5.
Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev 2011;10(3):319–29.PubMedCrossRef
6.
Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007;128(1):83–91.PubMedCrossRef
7.
Marincheva-Savcheva G, Subramanian S, Qadir S, Figueroa A, Truong Q, Vijayakumar J, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol 2011;57(25):2507–15.PubMedCrossRef
8.
Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009;135(1):4–13.PubMedCrossRef
9.
Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229–38.PubMedCrossRef
10.
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008;105(2):652–6.PubMedCrossRef
11.
Yoshioka K, Ueno Y, Tanaka S, Nagai K, Onitake T, Hanaoka R, et al. Role of natural killer T cells in the mouse colitis-associated colon cancer model. Scand J Immunol 2012;75(1):16–26.PubMedCrossRef
12.
Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011;165(5):953–65.PubMedCrossRef
13.
Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18(1):3–10.PubMedCrossRef
14.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436–44.PubMedCrossRef
15.
Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267(2):204–15.PubMedCrossRef
16.
Chianelli M, Mather SJ, Martin-Comin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 1997;18(5):437–55.PubMedCrossRef
17.
Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997;24(6):579–86.PubMedCrossRef
18.
D’Alessandria C, di Gialleonardo V, Chianelli M, Mather SJ, de Vries EF, Scopinaro F, et al. Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol 2010;12(5):539–46.PubMedCrossRef
19.
Signore A, Chianelli M, Toscano A, Monetini L, Ronga G, Nimmon CC, et al. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nucl Med Commun 1992;13(10):713–22.PubMed
20.
Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J Nucl Med 2000;41(2):242–9.PubMed
21.
Signore A, Picarelli A, Annovazzi A, Britton KE, Grossman AB, Bonanno E, et al. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 2003;24(3):305–16.PubMedCrossRef
22.
Di Gialleonardo V, Signore A, Glaudemans AWJM, Dierckx RA, De Vries EF. N-(4-18F-Fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med 2012;53:679–86. doi:10.​2967.PubMedCrossRef
23.
24.
Bøyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974;4(4):269–74.PubMed
25.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27(9):1533–9.PubMedCrossRef
26.
Akaike H. Data analysis by statistical models. No To Hattatsu 1992;24(2):127–33.PubMed
27.
Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983;130(5):2203–8.PubMed
Metadata
Title
Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
Authors
Valentina Di Gialleonardo
Alberto Signore
Antoon T. M. Willemsen
Jurgen W. A. Sijbesma
Rudi A. J. O. Dierckx
Erik F. J. de Vries
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2176-y

Other articles of this Issue 10/2012

European Journal of Nuclear Medicine and Molecular Imaging 10/2012 Go to the issue

Short Communication

FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis

Review Article

SIRT of liver metastases: physiological and pathophysiological considerations

Original Article

Reproducibility of planar 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure

Original Article

Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy

Editorial

PET/MRI and the revolution of the third eye

Editorial

Why do we need accreditation of nuclear medicine departments?